CYCART19
Live / Registered — Registered (as of 30 May 2023)
What this means for you
Registered since 30 May 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90766689
- Registration number
- 7064864
- Mark type
- Stylized text
- Filed
- 10 Jun 2021
- Published for opposition
- 14 Mar 2023
- Registered
- 30 May 2023
- Attorney of record
- CAMILLE M. MILLER
Goods and services
- Class 001 — Chemicals: bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research; placental-derived cells, chimeric antigen receptor (CAR) T cells, and placental-derived T cells with a chimeric antigen receptor (CAR), all for use in scientific, laboratory and medical research
- Class 005 — Pharmaceuticals: Cells and biological preparations intended for medical and clinical use, namely, blood, stem cells, placental-derived cells, umbilical cord cells, placental-derived T cells, chimeric antigen receptor (CAR) T cells, umbilical cord blood, and placental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; human amniotic membrane and human chorionic membrane intended for subsequent implantation; human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological products for medical use, namely, placental-derived natural killer cells, and placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen; biological tissue intended for use as a wound covering and burn dressing; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds and burns; and written instructional materials distributed in connection with the aforesaid goods; biological products for medical use, namely, placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen
Owner
- Celularity Inc., Florham Park, NJ, US
- Celularity Inc., Florham Park, NJ, US
- Celularity Inc., Florham Park, NJ, US
Prosecution history
- 30 May 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 30 May 2023 — REGISTERED-PRINCIPAL REGISTER
- 14 Mar 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Mar 2023 — PUBLISHED FOR OPPOSITION
- 22 Feb 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 06 Feb 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 03 Feb 2023 — EXAMINER'S AMENDMENT ENTERED
- 03 Feb 2023 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 03 Feb 2023 — EXAMINERS AMENDMENT E-MAILED
- 03 Feb 2023 — EXAMINERS AMENDMENT -WRITTEN
- 16 Dec 2022 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 16 Dec 2022 — EX PARTE APPEAL-INSTITUTED
- 16 Dec 2022 — JURISDICTION RESTORED TO EXAMINING ATTORNEY
- 16 Dec 2022 — EXPARTE APPEAL RECEIVED AT TTAB
- 16 Jun 2022 — NOTIFICATION OF FINAL REFUSAL EMAILED